Literature DB >> 28385249

Enhanced immune response to inactivated porcine circovirus type 2 (PCV2) vaccine by conjugation of chitosan oligosaccharides.

Guiqiang Zhang1, Peiyuan Jia2, Gong Cheng2, Siming Jiao2, Lishi Ren2, Shaoyang Ji2, Tao Hu3, Hongtao Liu4, Yuguang Du5.   

Abstract

This study aimed to investigate the effect of chitosan oligosaccharide (COS) conjugation on the immunogenicity of porcine circovirus type-2 (PCV2) vaccine. Two conjugates (PCV2-COS-1 and PCV2-COS-2) were designed by covalent conjugation of an inactivated PCV2 vaccine with COS, and administered to C57BL/6 mice three times at two-week intervals. The results indicate that, as compared to PCV2 alone group, the PCV2-COS conjugates remarkably enhanced both humoral and cellular immunity against PCV2 by promoting T lymphocyte proliferation and initiating a mixed Th1/Th2 response, including the elevated production of PCV-2 specific antibodies and up-regulated secretion of inflammatory cytokines. Noticeably, the immunization with PCV2-COS-1 conjugate displayed similar or even better immune-stimulating effects than that by PCV2/ISA206 (a commercialized adjuvant) and showed no infection or pathological signs at injection sites of the mice. Presumably, the covalent linkage of PCV2 vaccine to COS might be a viable strategy to increase the efficacy against PCV2-associated diseases.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adjuvant; Chitosan oligosaccharide; Conjugation; Porcine circovirus type 2 (PCV2); Vaccine

Mesh:

Substances:

Year:  2017        PMID: 28385249     DOI: 10.1016/j.carbpol.2017.02.058

Source DB:  PubMed          Journal:  Carbohydr Polym        ISSN: 0144-8617            Impact factor:   9.381


  8 in total

1.  Conjugation of chitosan oligosaccharides via a carrier protein markedly improves immunogenicity of porcine circovirus vaccine.

Authors:  Guiqiang Zhang; Peiyuan Jia; Hongtao Liu; Tao Hu; Yuguang Du
Journal:  Glycoconj J       Date:  2018-07-26       Impact factor: 2.916

2.  The Immunoenhancement Effects of Polyethylenimine-Modified Chinese Yam Polysaccharide-Encapsulated PLGA Nanoparticles as an Adjuvant.

Authors:  Yue Zhang; Pengfei Gu; Adelijiang Wusiman; Shuwen Xu; Haiyu Ni; Tianxin Qiu; Zhenguang Liu; Yuanliang Hu; Jiaguo Liu; Deyun Wang
Journal:  Int J Nanomedicine       Date:  2020-08-05

3.  The Positive Correlation of the Enhanced Immune Response to PCV2 Subunit Vaccine by Conjugation of Chitosan Oligosaccharide with the Deacetylation Degree.

Authors:  Guiqiang Zhang; Gong Cheng; Peiyuan Jia; Siming Jiao; Cui Feng; Tao Hu; Hongtao Liu; Yuguang Du
Journal:  Mar Drugs       Date:  2017-07-26       Impact factor: 5.118

4.  Immunogenicity evaluation of inactivated virus and purified proteins of porcine circovirus type 2 in mice.

Authors:  Xiaohui Liu; Ting Ouyang; Teng Ma; Hongsheng Ouyang; Daxin Pang; Linzhu Ren
Journal:  BMC Vet Res       Date:  2018-04-23       Impact factor: 2.741

Review 5.  Polysaccharides obtained from natural edible sources and their role in modulating the immune system: Biologically active potential that can be exploited against COVID-19.

Authors:  Jhonatas Rodrigues Barbosa; Raul Nunes de Carvalho Junior
Journal:  Trends Food Sci Technol       Date:  2021-01-04       Impact factor: 12.563

6.  Chitosan Oligosaccharides Coupling Inhibits Bacterial Biofilm-Related Antibiotic Resistance against Florfenicol.

Authors:  Xianghua Yuan; Jing Liu; Ruilian Li; Junlin Zhou; Jinhua Wei; Siming Jiao; Zhuo A Wang; Yuguang Du
Journal:  Molecules       Date:  2020-12-21       Impact factor: 4.411

7.  Swine Influenza Virus Infection Decreases the Protective Immune Responses of Subunit Vaccine Against Porcine Circovirus Type 2.

Authors:  Yuhang Sun; Jinlong Zhang; Zixuan Liu; Ying Zhang; Kehe Huang
Journal:  Front Microbiol       Date:  2021-12-24       Impact factor: 5.640

Review 8.  Porcine Circovirus Type 2 Vaccines: Commercial Application and Research Advances.

Authors:  Jinshuo Guo; Lei Hou; Jianwei Zhou; Dedong Wang; Yongqiu Cui; Xufei Feng; Jue Liu
Journal:  Viruses       Date:  2022-09-10       Impact factor: 5.818

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.